Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months

医学 内科学 累积发病率 伊马替尼 肿瘤科 甲磺酸伊马替尼 队列 达沙替尼 对数秩检验 生存分析 髓系白血病
作者
Nicola D. Roberts,David T Yeung,FRCPA,Haley Altamura,Wendy T Parker,Timothy P. Hughes
出处
期刊:Blood [Elsevier BV]
卷期号:122 (21): 254-254 被引量:15
标识
DOI:10.1182/blood.v122.21.254.254
摘要

![Graphic][1] Background The molecular response at 3 months (mo) after commencement of tyrosine kinase inhibitor (TKI) therapy for CML patients (pts) has prognostic significance and has been confirmed by many groups. Analyses by Marin, JCO 2012 and Neelakantan, Blood 2013 went further and suggest that measuring BCR-ABL at 3 mo is the only requirement to predict outcome, with BCR-ABL at later timepoints adding little useful information. However, Nazha (Haematologica 2013) using cytogenetic measurement suggest that assessing the 6 mo response for pts with a poor response at 3 mo may provide a better predictor of long-term outcome. Aim In this study, we aimed to dissect the prognostic importance of assessing both the 3 and 6 mo molecular response in our large cohort and determine whether a poor response at 3 mo identifies a group with high ongoing risk of treatment failure regardless of subsequent molecular response. Method We evaluated 528 pts enrolled in consecutive trials of first line imatinib from 2000-2009. Many pts were treated before alternative TKIs were available, but 89 switched. The utility of BCR-ABL as a predictor of death, progression (AP/BC/death: PFS) and treatment failure (according to ELN 2013: FFS) was assessed by ROC analysis, Kaplan-Meier survival with log rank test, and cumulative incidence with Fine & Gray regression for MMR. Pts were divided according to the 2013 ELN 3 and 6 mo molecular response definition: 3 mo, Optimal (Opt) ≤10% or Warning (Warn) >10%; 6 mo, Opt 10%. The Warn category requires more frequent monitoring and Fail mandates a therapy change. Results Optimal BCR-ABL threshold values at 3 mo for outcome prediction were concordant with Marin, JCO 2012: death 16.1%; progression 9.5%; failure 8.4%; MMR 1.4%, demonstrating the commutability of the international reporting scale. Consistent with other studies, responses after 4 years were significantly superior for pts ≤10% (Opt) compared with >10% (Warn) at 3 mo: survival 97% v 90%, P = .003; PFS 96% v 84%, P < .0001; FFS 83% v 42%, P < .0001; and MMR 89% v 42%, P < .0001. 100 pts met the BCR-ABL Warn criterion at 3 mo: 14 of these progressed; 4 before 6 mo and a further 7 before 12 mo. When modeling BCR-ABL measurements at 0, 1, 2, 3, 6 and 12 mo as a time-dependent continuous covariate in Cox regression, a BCR-ABL decrease at any time significantly reduced the risk of death ( P = .0002), progression ( P 10% at 3 mo. The Table and Figure detail outcomes at 4 years. Any reduction below 10% at 6 mo for pts in the 3 mo Warn category significantly reduced the subsequent risk of death, progression and failure, and increased MMR rates. Notably, there was no significant difference in outcome for pts >10% at 3 mo and <1% at 6 mo (Warn / Opt) compared to pts with an optimal response at both timepoints. View this table: Table. Outcome beyond 6 mo of therapy according to the ELN 3 and 6 mo molecular response definition Conclusion Our data confirms the importance of achieving BCR-ABL values of 10% or below at 3 mo after starting therapy. Based on the 3 mo assessment, the prognosis was significantly superior for these pts. Progression before the 6 mo timepoint occurred in 4% of pts with BCR-ABL >10% at 3 mo. However, the vast majority of pts with >10% at 3 mo continued therapy and the 6 mo BCR-ABL assessment provided important long-term prognostic information. Any reduction below 10% at 6 mo led to significantly superior outcomes, approximating those with optimal response at 3 mo. The impact and optimal timing of therapeutic intervention for pts in the poor risk category at 3 mo still needs to be determined in prospective studies and may require large patient cohorts. However, pts who are >10% at both 3 and 6 mo have inferior outcomes and are undoubtedly in need of a therapy change. ![Figure][2] Disclosures: Branford: Novartis: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Ariad: Honoraria, Research Funding. Yeung: Novartis: Honoraria, Research Funding; BMS: Honoraria. Hughes: Novartis: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau; BMS: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Ariad: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding. [1]: /embed/inline-graphic-2.gif [2]: pending:yes

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
雨品完成签到,获得积分10
刚刚
123321完成签到,获得积分10
刚刚
Bonlin完成签到,获得积分10
2秒前
doomedQL完成签到,获得积分10
3秒前
燕子完成签到 ,获得积分10
3秒前
3秒前
啦啦啦完成签到,获得积分10
3秒前
小白完成签到,获得积分10
4秒前
吴秋阳完成签到 ,获得积分10
4秒前
王老师完成签到 ,获得积分10
4秒前
skycool完成签到,获得积分10
5秒前
lujianqi发布了新的文献求助150
6秒前
晓风完成签到,获得积分0
7秒前
congyang完成签到,获得积分20
7秒前
淇淇完成签到 ,获得积分10
8秒前
平常的朝雪完成签到 ,获得积分10
8秒前
bigger.b完成签到,获得积分0
8秒前
lolo完成签到,获得积分10
8秒前
FR完成签到,获得积分10
8秒前
小芒果发布了新的文献求助10
8秒前
kobe完成签到 ,获得积分10
8秒前
5999完成签到 ,获得积分10
9秒前
6666666完成签到,获得积分10
9秒前
3475完成签到,获得积分10
9秒前
Firsterchao的应助被科研通管家采纳,获得10
9秒前
cdercder的应助被科研通管家采纳,获得10
9秒前
Hello的应助被科研通管家采纳,获得10
9秒前
吃人陈完成签到,获得积分10
9秒前
鱼鱼完成签到,获得积分10
9秒前
小二郎的应助被科研通管家采纳,获得10
9秒前
落寞万仇完成签到,获得积分10
9秒前
乐乐笑语的应助被科研通管家采纳,获得10
9秒前
小黑马完成签到,获得积分10
9秒前
桐桐的应助被科研通管家采纳,获得10
10秒前
粼望步完成签到,获得积分10
10秒前
10秒前
cdercder的应助被科研通管家采纳,获得10
10秒前
秒速五厘米完成签到,获得积分0
12秒前
称心小松鼠完成签到,获得积分10
13秒前
晨曦完成签到 ,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180111
求助须知:如何正确求助?哪些是违规求助? 9570235
关于积分的说明 21809184
捐赠科研通 7776198
什么是DOI,文献DOI怎么找? 3433262
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479039